News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development, the company said. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg’s leading medical oncology hub […] The post VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development a
Most retirees shop for dividend portfolios the same way people shop for cars: they focus on what they get today. A portfolio yielding $90,000 a year feels like the retirement equivalent of driving a Ferrari off the lot. Another portfolio paying only $45,000 can look more like a dependable Honda. The mistake is assuming the race ... The Dividend Portfolio That Starts Like A Honda And Ends Like A Ferrari
At 64, with $1.1 million in a Traditional IRA, tax-deferred cash flow is the point. With the 10-year Treasury at 4.50% and the 30-year at 4.94%, dividend yields have to earn their seat. The 10-year has swung between 4.43% and 4.56% in June alone, and that yield volatility is exactly what forced me to re-stack ... 64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
ABBV gains EU approval for Skyrizi in pediatric plaque psoriasis, expanding reach in younger patients with a new weight-based dosing option.
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer embedded in its business and a share price that looks like a mistake.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
AbbVie’s model fair value is held at US$253.55 per share, signaling no change to the core price target after factoring in the proposed Apogee Therapeutics acquisition. Research around the US$10.9b deal points to a split view, with some analysts highlighting the immunology and atopic dermatitis opportunity, while others question how much value the company can capture against rising competition. As you read on, you will see how these mixed signals are shaping the evolving AbbVie story and what...
Lilly's expected global sales of $137 billion in 2032 will be driven by its weight-loss drugs.
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 1.5% and the St
Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.
By selecting high-quality stocks with above-average yields, the iShares Core High Dividend ETF generates sustainable income.
AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.
AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
Companies in The News Are: APGE, ABBV, DLR, META, SNDK
European Commission Expands Skyrizi Label to Younger PatientsAbbVie (NYSE:ABBV) has received approval from the European Commission to use Skyrizi (risankizumab) in children and adolescents aged six years and older with moderate-to-severe plaque psoriasis who are eligible for systemic treatment. The authorization broadens the medicine’s reach within Europe and provides a new treatment option for younger patients living with the chronic inflammatory skin condition.
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next? The Apogee setup is the template buyers are chasing: late-stage clinical data, a meaningful addressable market, ... 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
With a 5-Year Average Dividend Growth Rate of 6.33%, AbbVie Inc. (NYSE:ABBV) is included among the Top 11 Dividend Kings to Buy for Safe Dividend Growth. On June 22, Wells Fargo maintained an Overweight rating on AbbVie Inc. (NYSE:ABBV). It also set a $260 price target on the shares. The firm said AbbVie’s reported bid […]
An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline.
The gains showed increasing investor interest in companies benefiting from rising demand for AI infrastructure, large-scale chip manufacturing projects, and acquisitions.
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 10 Stocks Paying Off Big Time. Apogee Therapeutics soared to a fresh all-time high on Monday, as investors gobbled up shares following announcements that it is set to be acquired by pharmaceutical giant AbbVie Inc. at a 49 percent premium. In a joint statement on the same […]
The company is already renowned by many as a giant in the segment.
On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.
AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.
Yahoo Finance Senior Reporter Brooke DiPalma joins Josh Lipton in highlighting the day's biggest stories and stock moves, including AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE) and Coca-Cola's (KO) latest legal showdown with the IRS in US appeals court.
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.9% and